ASA raps Voy over ‘misleading’ low testosterone ads

The watchdog ruled that three poster ads and two paid-for Facebook ads by Voy “must not appear again in their current form”.

Facebook logo
The ASA said Voy presented low testosterone as a "definitive diagnosis for symptoms" (Shutterstock)

The Advertising Standards Authority (ASA) has ruled against online pharmacy Voy over complaints that ads for its low testosterone service were “misleading”.

In a decision published today, the watchdog found that three poster ads and two paid-for Facebook video ads seen in January broke advertising regulations.

Read more: ASA bans weight loss pill ads by Voy, Juniper and MedExpress 

It said the posters and one of the Facebook ads “referenced symptoms and characteristics that in isolation were common and could arise for many reasons”.

It added that Voy “exaggerated the likely connection” between these symptoms and low testosterone levels in the ads, and that they “were therefore misleading”.

And it found that the other Facebook ad made claims about the prevalence of low testosterone levels in men under 30 “without adequate substantiation”.

Poster ads

One poster featured text that said “Feeling irritable? It might be low testosterone. Get an at-home test”.

The other two featured text that said “If you’re feeling fatigued, it might be low testosterone. Get an at-home test”.

Read more: ASA rules against Numan and BioID Health over low testosterone ads 

The ASA said the British Society for Sexual Medicine (BSSM) “only recommended testosterone deficiency screening for fatigue and irritability in conjunction with other symptoms”.

It added that the Endocrine Society recommended diagnosing hypogonadism with men “who presented with plural symptoms and signs of testosterone deficiency”.

The watchdog therefore considered that the ads “suggested a strong connection between those symptoms and low testosterone levels which was not substantiated”.

Facebook ads

One of the Facebook ads featured a personal testimonial from TV broadcaster Jason Fox, which included text listing symptoms such as “low energy”, “no motivation”, “anxiety” and “strength and muscle loss”.

Fox also described challenges such as “failing not only at home, but work” and “spiralling out of control”.

Read more: First oral weight loss drug ads banned by watchdog 

The ASA noted that the ad did not make any reference to a blood test kit, but said it presented low testosterone as the explanation for Fox’s symptoms, so consumers “would infer it had been a definitive diagnosis”.

The watchdog also said the inclusion of “anxiety” as a symptom of low testosterone in the ad was misleading, as neither the BSSM nor the Endocrine Society “explicitly mentioned” anxiety as a symptom of low testosterone.

It concluded that the ad “suggested a strong connection between that symptom and low testosterone levels which was not substantiated”.

Read more: ‘Irresponsible’: ASA raps SheMed over Reddit weight loss ad 

The other Facebook ad that the ASA ruled against stated that “low testosterone sneaks up on one in four men over 30”.

Voy defended this claim by providing an observational study of 1,475 men aged between 30 and 79 years from Boston, United States, which found that 24% had total testosterone below 300 ng/dl.

Read more: Pharmacy and menopause clinic partner on testosterone service 

But the ASA said this figure was unrepresentative, as 373 men without symptoms had already been excluded from the sample.

And it said the 24% figure was further misleading because the study found that only 5.6% of participants met the criteria for symptomatic androgen deficiency, while the ad implied that “one in four men over 30” had symptomatic androgen deficiency.

Read more: Ads regulator raps Voy over Black Friday weight loss emails 

The watchdog also said Voy’s ad “did not make clear” that the figure came from a study of men “preselected on the basis of exhibiting those symptoms”.

It therefore concluded that the claim had not been adequately substantiated and the ad “was likely to mislead”.

Voy’s response

Voy said that the ads referencing fatigue, irritability and anxiety as low testosterone symptoms “did not state or imply that the advertised symptoms were definitively caused by low testosterone”.

And it said language used in the ads was “deliberately conditional, using claims such as ‘might be’ and ‘might have’ to indicate a possible cause of the common symptoms”.

Read more: Online pharmacies named in weight loss jab investigation 

The online pharmacy added that the claim that “low testosterone sneaks up on one in four men over 30” was “not misleading and was substantiated by academic research”.

It said the ad “referred to the prevalence of low testosterone levels, not to a clinical diagnosis of testosterone deficiency”, and that testosterone deficiency was defined “by both low levels of testosterone and relevant symptoms”.

ASA ruling

The ASA ruled that the three poster ads and two Facebook ads “must not appear again in their current form”.

It said it had also told Voy to “not exaggerate the likely connection between common symptoms and low testosterone levels or present low testosterone levels as a definitive diagnosis for symptoms”.

Read more: Social posts advertising weight loss jabs via affiliate links banned 

“Further, they should not make claims about the occurrence of low testosterone levels in the male population without adequate substantiation,” the watchdog added.

It comes after the ASA took action earlier this month against Voy, Juniper and MedExpress for promoting prescription-only weight loss pills to the public.

And it follows the watchdog upholding two complaints in August against BioID Health and one against Numan over Facebook ads relating to testosterone services.

Declan Ryder

Read more by Declan Ryder

Declan joined C+D as a reporter in July 2026. He has previous bylines in The Drinks Business magazine and graduated with an MA in Journalism from City St George's, University of London with Distinction earlier this year.

Latest from Regulation

More from News